Therapeutic implications of IL-17A blockade in psoriasis.
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: LPuig@santpau.cat.
L
L
Puig
Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, España.
J M
JM
Carrascosa
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000502:physiology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D012867:Skin / Q000276:immunology; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; C508717:IL17A protein, human; D020381:Interleukin-17; C571216:brodalumab; C549079:ixekizumab; C555450:secukinumab